Brought to you by 
Rosetta and Gemini Genomics look for disease genes
06 Dec 2000
Executive Summary
Two genomics firms, Rosetta Inpharmatics and Gemini Genomics, are combining their technologies to identify and characterize genes associated with common human diseases. The two companies will fund their own research and equally share rights to any resulting intellectual property, which they plan to license to third-party collaborators.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rosetta and Gemini Genomics look for disease genes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice